Highest-materiality recent filing
HCA Q2 prelim revenue $20.23B, EPS $7.62; cuts FY2026 guidance on payer mix shift
Q2 2026 revenue $20.230B (+8.7% YoY); net income $1.699B ($7.62 diluted EPS) vs $1.653B ($6.83) in Q2 2025.
HCA Healthcare EVP & Chief Clinical Officer Michael Cuffe to step down Aug 31, 2026
Dr. Michael Cuffe to step down as EVP and Chief Clinical Officer effective August 31, 2026.
HCA Inc. issues $3B in senior notes across three tranches maturing 2031-2036
Issued $1B of 4.700% notes due 2031, $750M of 5.000% notes due 2033, and $1.25B of 5.300% notes due 2036.
All nine director nominees elected; votes for ranged from 173.1M (DeParle) to 193.7M (Hazen) shares.
HCA Inc. proposes senior notes offering; to redeem $2.5B in near-term notes
HCA Inc. proposes public offering of senior notes; terms not yet set.
HCA Q1 revenue up 4.3% to $19.1B; EPS rises 10.9% to $7.15; declares $0.78 dividend
Revenues $19.109B, net income $1.620B (+0.6% YoY); diluted EPS $7.15 (+10.9% YoY).
HCA sets 2026 exec comp: CEO target 175% of salary; board member Dennis to retire
CEO Samuel Hazen target award 175% of base; CFO/COO 125%; other named execs 100%.
HCA Healthcare Q4 EPS $8.14 (up 44.6%), revenue $19.5B, $10B buyback authorized
Q4 revenue $19.513B (+6.7% YoY); net income $1.878B (+30.6%); adjusted EBITDA $4.114B (+10.8%).
HCA issues $3.25B senior notes: 4.30% 2030, 4.60% 2032, 4.90% 2035, 5.70% 2055
$500M 4.30% notes due 2030, $1B 4.60% due 2032, $1B 4.90% due 2035, $750M 5.70% due 2055.
HCA subsidiary proposes senior notes offering, plans to redeem $1.5B 5.875% notes due 2026
HCA Inc. proposes public offering of senior unsecured notes; terms (maturity, rate, amount) to be set at pricing.
HCA Healthcare Q3 EPS $6.96, revenue $19.2B, raises 2025 guidance
Diluted EPS $6.96 (up 42.6% YoY); net income $1.643B (up 29.4%).
HCA Q2 revenue $18.6B (+6.4%), EPS $6.83 (+23.5%); raises 2025 guidance
Revenue $18.605B (+6.4% YoY); net income $1.653B (+13.1% YoY).
HCA Healthcare appoints John W. Chidsey, III as independent director, effective July 15
Board expands from 9 to 10 directors; Chidsey will serve on Audit & Compliance, Compensation, and Patient Safety & Quality of Care committees.
HCA Inc. establishes $4B commercial paper program, guaranteed by HCA Healthcare
Issuer HCA Inc. can issue up to $4B in unsecured commercial paper notes with maturities up to 397 days.
HCA stockholders OK 13.15M share increase for equity plan; officer exculpation amendment passed
Stockholders approved First Amendment to 2020 Stock Incentive Plan, adding 13,150,000 shares (total reserve now 18,542,144).
HCA Healthcare Q1 revenue $18.3B, EPS $6.45, adjusted EBITDA $3.73B, reaffirms guidance
Revenue $18.321B (+5.7% YoY); net income $1.610B, diluted EPS $6.45 (vs $5.93 prior year).
HCA director Crofton to retire at April 2025 annual meeting; exec incentive program adopted
Meg G. Crofton to retire from HCA board effective April 24, 2025 annual meeting.
HCA Inc. issues $5.25B of senior notes across six tranches maturing 2028-2055
Total $5.25B: $700M 5.000% notes due 2028, $300M floating-rate notes due 2028, $750M 5.250% due 2030.
HCA enters $8.0B unsecured revolver, terminates secured credit facilities
New $8.0B senior unsecured revolving credit facility with 5-year maturity dated Feb 20, 2025.
HCA subsidiary HCA Inc. proposes offering of senior notes; final terms (maturity, rate, amount) depend on market conditions.
HCA Q4 revenue $18.3B, EPS $5.63; 2025 EPS guidance $24.05-$25.85; $10B buyback authorized
Q4 revenue $18.285B (+5.7% YoY); net income $1.438B ($5.63 diluted EPS) vs $1.607B ($5.93) in 4Q23; includes $0.60/sh hurricane impact.
Revenue $17.487B (up 7.9% YoY), net income $1.270B (up 17.7%), diluted EPS $4.88 vs $3.91.
HCA Healthcare issues $3B in senior notes across three tranches with rates 5.45%-5.95%
$3B total: $750M 5.45% notes due 2031 (now $1.75B total), $1.25B 5.45% notes due 2034, $1B 5.95% notes due 2054.
HCA Healthcare issues $3B senior notes in three tranches; 2031 notes fungible with existing
$750M of 5.450% Senior Notes due 2031, issued as additional notes under existing indenture and fungible with prior $1B issue.
HCA Q2 2024 rev $17.49B, EPS $5.53, raises FY guidance
Revenue $17.492B (+10.3% YoY); net income $1.461B ($5.53 diluted EPS) vs $1.193B ($4.29).
William B. Rutherford retires as EVP/CFO effective May 1, 2024; Christopher Wyatt succeeds as principal accounting officer.
HCA Q1 revenue up 11% to $17.34B, EPS $5.93; reaffirms FY guidance
Revenue $17.339B (+11.2% YoY); net income $1.591B ($5.93 diluted EPS) vs $1.363B ($4.85).
HCA Healthcare sets CFO Michael Marks' 2024 PEP award at 65% of base, rising to 110%
Compensation Committee approved 2024 Executive Officer PEP for CFO Michael A. Marks, effective May 1, 2024.
HCA appoints McAlevey as EVP – Chief Legal & Admin Officer; CFO Rutherford to retire May 1
CEO Hazen target award 170% of base salary; COO Foster 125%; CFO Rutherford retiring May 1, 2024, not participating.
HCA issues $4.5B of senior notes across four tranches (2031-2064)
$1.0B of 5.450% notes due 2031, $1.3B of 5.600% notes due 2034, $1.5B of 6.000% notes due 2054, $0.7B of 6.100% notes due 2064.
HCA Healthcare issues $4.5B senior notes in four tranches with maturities from 2031 to 2064
$1.0B of 5.450% notes due 2031, $1.3B of 5.600% notes due 2034.
Q4 2023 revenue $17.303B (+11.6% YoY); net income $1.607B ($5.93 diluted EPS) vs $2.081B ($7.28) in Q4 2022, which included $1.326B gain.
HCA targets 4-6% EBITDA, 8-12% EPS growth over 5 yrs; 2024 within ranges
Adjusted EBITDA growth target of 4% to 6% annually over next five years.
HCA Healthcare Q3 revenue $16.21B, EPS $3.91; FY 2023 guidance revised; dividend $0.60
Revenue $16.213B (+8.3% YoY); net income $1.079B ($3.91 diluted EPS, flat vs $3.91 prior year).
HCA Healthcare Q2 2023 revenue $15.86B; EPS $4.29; raises 2023 guidance
Revenue $15.861B, up 7% YoY; net income $1.193B, diluted EPS $4.29 (vs $3.90).
HCA Healthcare reports data security incident affecting patient contact and appointment information
Unknown unauthorized party posted patient names, email, phone, birth date, gender, service date, and appointment location on an online forum.
Segments changed from two to three groups; historical segment data in 2022 10-K retrospectively revised.
HCA Healthcare issues $3.25B in three tranches of senior notes
Issued $1B 5.200% notes due 2028, $1.25B 5.500% notes due 2033, $1B 5.900% notes due 2053.
HCA Healthcare issues $3.25B senior notes in three tranches
$1.0B of 5.200% Senior Notes due 2028, $1.25B of 5.500% due 2033, $1.0B of 5.900% due 2053.
HCA Healthcare Q1 EPS $4.85 beats prior year; raises 2023 revenue and profit guidance
Q1 revenues $15.591B (up 4.3% YoY); net income $1.363B, diluted EPS $4.85 vs $4.14.
HCA Healthcare shareholders approve 2023 ESPP and re-elect all directors
Shareholders approved the 2023 Employee Stock Purchase Plan, which reserves 10M shares for employee purchases.
HCA Healthcare 2023 Senior Officer PEP: CEO target 170% of base, 80% EBITDA weight
CEO Samuel N. Hazen target award 170% of base salary; CFO William B. Rutherford and COO Jon M. Foster each 125%.
HCA Healthcare details COO Foster's compensation: base to $1M, $3.75M equity grant
Base salary increased from $918,596 to $1,000,000 effective January 1, 2023.
HCA Healthcare Q4 net income $2.08B ($7.28 EPS); revenue $15.5B; new $3B buyback
Q4 revenue $15.50B (+2.9% YoY); net income $2.08B ($7.28 diluted EPS) incl $1.33B facility-sale gains.
HCA Healthcare amends credit facilities: revolver increased to $3.5B, LIBOR replaced with Term SOFR
Revolving credit commitments under Cash Flow Credit Facility raised from $2.0B to $3.5B; maturity extended to June 30, 2026.
HCA Healthcare amends bylaws to update director nomination and proxy solicitation requirements
Board adopted Third Amended and Restated Bylaws effective December 19, 2022.
HCA Healthcare promotes Jon Foster to EVP & COO; creates third operating group
Jon Foster, previously President of American Group, named EVP & COO effective January 1, 2023.
HCA Healthcare Q3 revenue down 2% to $14.97B; net income $1.13B ($3.91 EPS)
Revenue fell 2% YoY to $14.97B; net income $1.13B ($3.91 EPS) vs $2.27B ($7.00 EPS) prior year which included $1.05B sale gains.
HCA President – National Group Charles J. Hall to retire on Dec 31, 2022
Charles J. Hall, President – National Group, will retire effective December 31, 2022.
HCA Healthcare Q2 2022 net income down 20% to $1.155B; EPS $3.90 vs $4.36 YoY
Revenue $14.820B (+2.7% YoY); net income $1.155B ($3.90 EPS) vs $1.450B ($4.36) in Q2 2021.
On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027.
Retirement of Meg G. Crofton from the
As previously announced, William B. Rutherford, HCA Healthcare, Inc.’s (the “Company’s”) Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer notified the Company of his intent to retire, effective May 1, 2024.
In conjunction with Mr. Rutherford’s retirement, Christopher F. Wyatt, age 47, will succeed Mr. Rutherford as principal accounting officer, effective May 1, 2024.
William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.
• 85% of base salary for Michael R. McAlevey, our Senior Vice President and Chief Legal Officer (to be increased to 100%, effective April 1, 2024, in connection with Mr. McAlevey’s appointment as Executive Vice President – Chief Legal and Administrative Officer).
On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
On October 20, 2022, the Board of Directors of HCA Healthcare, Inc. (the “Company”) appointed Jon M. Foster as the Executive Vice President and Chief Operating Officer of the Company effective January 1, 2023.
On August 15, 2022, Charles J. Hall, the President — National Group of HCA Healthcare, Inc. (the “Company”), informed the Company that he will retire from the Company, effective December 31, 2022.
On January 24, 2022, the Company’s Board of Directors (the “Board”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrea B. Smith to the Company’s Board effective January 26, 2022, increasing the number of directors on the Board from 10 to 11.
Dr. Jonathan B. Perlin, President - Clinical Operations Group and Chief Medical Officer, notified HCA Healthcare, Inc. (the “Company”) on September 16, 2021 that he had accepted the role of president and CEO of The Joint Commission and will assume his new role on March 1, 2022.
Max materiality 0.85 · Median 0.60 · Most common event earnings